Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

scientific article published on 26 June 2009

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JCHROMB.2009.06.029
P698PubMed publication ID19589736

P50authorJos BeijnenQ23771643
P2093author name stringA H Schinkel
J H M Schellens
H Rosing
S C Linn
R H T Koornstra
S F Teunissen
P433issue24
P921main subjecttamoxifenQ412178
P304page(s)2519-2529
P577publication date2009-06-26
P1433published inJournal of Chromatography B Analytical Technologies in the Biomedical and Life SciencesQ2422407
P1476titleDevelopment and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.
P478volume877

Reverse relations

cites work (P2860)
Q38243454Application of micellar liquid chromatography for the determination of antitumoral and antiretroviral drugs in plasma
Q37811317Bioanalytical methods for determination of tamoxifen and its phase I metabolites: A review
Q36109257CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Q30668728Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis
Q42929605Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study
Q38604479Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.
Q37597968Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry
Q58767256Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy
Q64886091New UPLC–MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients.
Q35547180Study of tamoxifen urinary metabolites in rat by ultra-high-performance liquid chromatography time-of-flight mass spectrometry
Q36976844Tamoxifen mimics the effects of endogenous ovarian hormones on repeated seizures induced by pentylenetetrazole in rats
Q48584159The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen
Q45905355The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
Q36197839UPLC-MS/MS method for the determination of tobacco-specific biomarker NNAL, tamoxifen and its main metabolites in rat plasma

Search more.